C Patrono

Summary

Affiliation: University of Chieti
Country: Italy

Publications

  1. ncbi Antiplatelet drugs
    Gustav Born
    William Harvey Research Institute, St Bartholomew's and the Royal London School of Medicine and Dentistry, University of London, London
    Br J Pharmacol 147:S241-51. 2006
  2. ncbi Efficacy and safety of aspirin in the long-term management of atherothrombosis
    Carlo Patrono
    Haematologica 87:6-8. 2002
  3. ncbi Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus
    Francesca Santilli
    Center of Excellence on Aging and Department of Medicine, University of Chieti G. D'Annunzio Schools of Medicine and Pharmacy, Chieti, Italy
    J Am Coll Cardiol 47:391-7. 2006
  4. ncbi Drug insight: aspirin resistance--fact or fashion?
    Carlo Patrono
    University of Rome La Sapienza, Ospedale Sant Andrea, Via di Grottarossa 1035, 00189 Rome, Italy
    Nat Clin Pract Cardiovasc Med 4:42-50. 2007
  5. ncbi Aspirin: promise and resistance in the new millennium
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Arterioscler Thromb Vasc Biol 28:s25-32. 2008
  6. ncbi Aspirin: new cardiovascular uses for an old drug
    C Patrono
    Department of Medicine and Aging, University of Chieti G D Annunzio School of Medicine, Chieti, Italy
    Am J Med 110:62S-65S. 2001
  7. ncbi Low-dose aspirin for the prevention of atherothrombosis
    Carlo Patrono
    Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
    N Engl J Med 353:2373-83. 2005
  8. ncbi Aspirin resistance: definition, mechanisms and clinical read-outs
    C Patrono
    University of Rome 'La Sapienza, Rome, Italy
    J Thromb Haemost 1:1710-3. 2003
  9. ncbi The PGH-synthase system and isozyme-selective inhibition
    Carlo Patrono
    Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
    J Cardiovasc Pharmacol 47:S1-6. 2006
  10. ncbi Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?
    C Patrono
    Department of Medicine and Aging, University of Chieti, G d Annunzio School of Medicine, Italy
    Thromb Res 92:S7-12. 1998

Collaborators

Detail Information

Publications62

  1. ncbi Antiplatelet drugs
    Gustav Born
    William Harvey Research Institute, St Bartholomew's and the Royal London School of Medicine and Dentistry, University of London, London
    Br J Pharmacol 147:S241-51. 2006
  2. ncbi Efficacy and safety of aspirin in the long-term management of atherothrombosis
    Carlo Patrono
    Haematologica 87:6-8. 2002
  3. ncbi Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus
    Francesca Santilli
    Center of Excellence on Aging and Department of Medicine, University of Chieti G. D'Annunzio Schools of Medicine and Pharmacy, Chieti, Italy
    J Am Coll Cardiol 47:391-7. 2006
    ....
  4. ncbi Drug insight: aspirin resistance--fact or fashion?
    Carlo Patrono
    University of Rome La Sapienza, Ospedale Sant Andrea, Via di Grottarossa 1035, 00189 Rome, Italy
    Nat Clin Pract Cardiovasc Med 4:42-50. 2007
    ..Gaining such knowledge could result in improved care of patients and might avoid the requesting of unnecessary platelet function tests of unproven clinical significance...
  5. ncbi Aspirin: promise and resistance in the new millennium
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Arterioscler Thromb Vasc Biol 28:s25-32. 2008
    ....
  6. ncbi Aspirin: new cardiovascular uses for an old drug
    C Patrono
    Department of Medicine and Aging, University of Chieti G D Annunzio School of Medicine, Chieti, Italy
    Am J Med 110:62S-65S. 2001
    ..Because of safety considerations, physicians are encouraged to use the lowest dose of aspirin shown effective in each clinical setting [Table-see text]...
  7. ncbi Low-dose aspirin for the prevention of atherothrombosis
    Carlo Patrono
    Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
    N Engl J Med 353:2373-83. 2005
  8. ncbi Aspirin resistance: definition, mechanisms and clinical read-outs
    C Patrono
    University of Rome 'La Sapienza, Rome, Italy
    J Thromb Haemost 1:1710-3. 2003
  9. ncbi The PGH-synthase system and isozyme-selective inhibition
    Carlo Patrono
    Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
    J Cardiovasc Pharmacol 47:S1-6. 2006
    ....
  10. ncbi Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?
    C Patrono
    Department of Medicine and Aging, University of Chieti, G d Annunzio School of Medicine, Italy
    Thromb Res 92:S7-12. 1998
    ....
  11. ncbi Isoprostane formation and inhibition in atherothrombosis
    Carlo Patrono
    Department of Pharmacology, Universita di Roma La Sapienza, Ospedale Sant Andrea, Via di Grottarossa 1035, 00189 Rome, Italy
    Curr Opin Pharmacol 5:198-203. 2005
    ..Clinical studies support the hypothesis that enhanced lipid peroxidation may contribute, at least in part, to persistent platelet activation...
  12. ncbi Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Carlo Patrono
    University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy
    Chest 126:234S-264S. 2004
    ....
  13. ncbi [Expert consensus document on the use of antiplatelet agents]
    Carlo Patrono
    Rev Esp Cardiol 57:963-80. 2004
  14. ncbi Measurement of cyclooxygenase isozyme inhibition in humans: exploring the clinical relevance of biochemical selectivity
    C Patrono
    Department of Medicine and Ageing, Cattedra di Farmacologia, Università di Chieti G d Annunzio, Via dei Véstini no 31, Chieti 66013, Italy
    Clin Exp Rheumatol 19:S45-50. 2001
    ..The clinical relevance of biochemical selectivity has to be studied in large GI outcome trials with adequate statistical power to detect realistic differences in these relatively rare events...
  15. ncbi Determinants of the interindividual variability in response to antiplatelet drugs
    B Rocca
    Center of Excellence on Aging, G. d'Annunzio University Foundation, Chieti, Italy
    J Thromb Haemost 3:1597-602. 2005
    ..Moreover, we have no controlled evidence that changing therapy is a more effective strategy than maintaining an evidence-based therapy...
  16. ncbi Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers
    P Patrignani
    Department of Medicine and Aging, University of Chieti G D Annunzio School of Medicine, Chieti, Italy
    Circulation 102:539-45. 2000
    ..We performed a randomized, double-blind, placebo-controlled study of the effects of vitamin E (300, 600, and 1200 mg/d, each dose for 3 consecutive weeks) on 8-iso-PGF(2alpha) and TXA(2) biosynthesis in 46 moderate cigarette smokers...
  17. ncbi Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo
    R Landolfi
    Department of Medicine, Catholic University School of Medicine, Rome, Italy
    Blood 80:1965-71. 1992
    ..This in vivo abnormality in platelet biochemistry can be largely suppressed by low doses of aspirin...
  18. ncbi Oxidative stress and platelet activation in homozygous homocystinuria
    G Davi
    Center of Excellence on Aging, Department of Biomedical Sciences, University of Chieti G D Annunzio, Chieti, Italy
    Circulation 104:1124-8. 2001
    ....
  19. ncbi Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus
    F Santilli
    Centre of Excellence on Aging, G d Annunzio University Foundation, Chieti, Italy
    J Thromb Haemost 8:828-37. 2010
    ..Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus...
  20. ncbi Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance"
    Francesca Santilli
    Center of Excellence on Aging, G d Annunzio University Foundation, Chieti, Italy
    J Am Coll Cardiol 53:667-77. 2009
    ..This study was conducted to assess the thromboxane (TX) dependence of biochemical and functional indexes used to monitor the effect of low-dose aspirin...
  21. ncbi Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment
    F Santilli
    Center of Excellence on Aging, G d Annunzio University Foundation, Chieti, Italy
    J Thromb Haemost 8:914-22. 2010
    ..Thromboembolism is a relatively common complication of chronic heart failure (HF) and the place of antiplatelet therapy is uncertain...
  22. ncbi Aspirin, 110 years later
    C Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    J Thromb Haemost 7:258-61. 2009
    ..secondary prevention...
  23. ncbi Release of contracting autacoids by aortae of normal and atherosclerotic rabbits
    P Patrignani
    Laboratory of Cardiovascular Pharmacology, University of Chieti G D Annunzio School of Medicine, Italy
    J Cardiovasc Pharmacol 20:S208-10. 1992
    ..3 vs. 5 +/- 0.5 pg/cm2, mean +/- SEM, n = 16). We conclude that enhanced formation of vasoconstrictor autacoids may contribute to altered vasomotion of atherosclerotic blood vessels...
  24. ncbi Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects
    Marta L Capone
    Department of Medicine and Center of Excellence on Aging, G. D'Annunzio University, School of Medicine, and G. d'Annunzio University Foundation, Chieti, Italy
    Circulation 109:1468-71. 2004
    ..CONCLUSIONS: The regular administration of naproxen 500 mg BID can mimic the antiplatelet COX-1 effect of low-dose aspirin. Naproxen, unlike aspirin, decreased prostacyclin biosynthesis in vivo...
  25. ncbi The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids
    G Santini
    Division of Pharmacology, Department of Medicine and Aging, G. D'Annunzio University of Chieti School of Medicine, Italy
    Clin Pharmacol Ther 70:475-83. 2001
    ..This effect may represent a readily measurable surrogate marker of their clinical efficacy for dose-finding studies...
  26. ncbi Biosynthesis and pharmacological modulation of thromboxane in humans
    C Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Circulation 81:I12-5; discussion I22-3. 1990
    ..Finally, TXA2-dependent glomerular damage, as seen in lupus nephritis, might represent a unique therapeutic target for receptor antagonists and/or tissue-selective synthase inhibitors...
  27. ncbi Human eicosanoid biosynthesis and metabolism
    C Patrono
    Department of Pharmacology, University of Chieti School of Medicine, Italy
    Mt Sinai J Med 59:157-62. 1992
    ..Application of the same investigative approach to other recently identified products of arachidonate metabolism (2) may provide further insight into the pathophysiologic significance of this complex mediator system...
  28. ncbi NOS evaluations in human dental pulp-capping with MTA and calcium-hydroxide
    C D'Arcangelo
    Department of Stomatology and Oral Sciences, University of Chieti, Chieti, Italy
    Int J Immunopathol Pharmacol 20:27-32. 2007
    ..Our results suggest that there are differences in localization and expression between eNOS and iNOS in dental pulp. Our study has helped us to better understand the effects that calcium hydroxide and MTA have on pulp tissue...
  29. ncbi Lipid peroxidation in diabetes mellitus
    Giovanni Davi
    Center of Excellence on Aging, University of Chieti G D Annunzio School of Medicine, Chieti, Italy
    Antioxid Redox Signal 7:256-68. 2005
    ..e., isoprostanes), and the association between isoprostane formation and platelet activation. Finally, possible targets of antioxidant therapy for diabetic vascular complications will be discussed...
  30. ncbi The P2Y12 receptor: no active metabolite, no party
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Nat Rev Cardiol 6:271-2. 2009
    ..Impaired platelet inhibition reflects inadequate plasma levels of active metabolites, and not differences in platelet P2Y12 receptor function...
  31. ncbi Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Carlo Patrono
    Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Chest 133:199S-233S. 2008
    ....
  32. ncbi Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration
    Giovanni Davi
    Center of Excellence on Aging and Department of Medicine, University of Chieti G d Annunzio Schools of Medicine and Pharmacy, Chieti, Italy
    Circulation 107:3199-203. 2003
    ..We also investigated the relationship between inflammatory markers and F2-isoprostane formation in this setting...
  33. ncbi Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
    Carlo Patrono
    ESC Task Force on Antiplatelets, University of Rome La Sapienza, , Via di Grottarossa, 1035, 00189 Roma, Italy
    Eur Heart J 25:166-81. 2004
  34. ncbi The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
    B Rocca
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    J Thromb Haemost 10:1220-30. 2012
    ..We hypothesized that faster recovery of platelet cyclooxygenase-1 activity may explain incomplete thromboxane (TX) inhibition during the 24-h dosing interval...
  35. ncbi Insulin resistance as a determinant of platelet activation in obese women
    Stefania Basili
    Department of Medical Therapy, University of Rome La Sapienza, Rome, Italy
    J Am Coll Cardiol 48:2531-8. 2006
    ..05) without changes in body weight. CONCLUSIONS: Insulin resistance is a major determinant of platelet activation in female obesity...
  36. ncbi Nutraceuticals in diabetes and metabolic syndrome
    Giovanni Davi
    Center of Excellence on Aging, G d Annunzio University Foundation, Chieti, Italy
    Cardiovasc Ther 28:216-26. 2010
    ....
  37. ncbi Efficacy and safety of low-dose aspirin in polycythemia vera
    Raffaele Landolfi
    Catholic University School of Medicine, Rome, Italy
    N Engl J Med 350:114-24. 2004
    ..The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial...
  38. ncbi Cyclooxygenase-2 expression and inhibition in atherothrombosis
    Francesco Cipollone
    Center of Excellence on Aging, G. D'Annunzio University of Chieti School of Medicine, Chieti, Italy
    Arterioscler Thromb Vasc Biol 24:246-55. 2004
    ....
  39. ncbi Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Mol Interv 9:31-9. 2009
    ..In this Review, the authors offer an assessment of drug pharmacokinetics and enzyme physiology that reconciles cardiovascular appraisals from a wide array of clinical data...
  40. ncbi Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies
    Raffaele Landolfi
    Institute of Internal Medicine and Geriatrics, Catholic Uinversity School of Medicine, Rome, Italy
    Semin Thromb Hemost 32:251-9. 2006
    ..Future studies should assess primarily the efficacy and safety of aspirin in essential thrombocythemia, and test the possible use of more aggressive antithrombotic strategies in high-risk polycythemic patients...
  41. ncbi Nonsteroidal antiinflammatory drugs: past, present and future
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Pharmacol Res 59:285-9. 2009
    ....
  42. ncbi Differential effects of leukotriene C4 on endothelin-1 and prostacyclin release by cultured vascular cells
    P Patrignani
    Laboratory of Cardiovascular Pharmacology, University of Chieti, G D Annuzio School of Medicine, Italy
    Pharmacol Res 27:281-5. 1993
    ..For both agonists, attenuation of this stimulatory effect was observed at higher concentrations, concomitant with but independent of enhanced prostacyclin biosynthesis...
  43. ncbi Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus
    R De Cristofaro
    Center of Excellence on Aging, G D Annunziou University School of Medicine and Pharmacy, Chieti, Italy
    J Thromb Haemost 1:250-6. 2003
    ..In conclusion, OS in T2DM involves circulating proteins and is associated with an unbalanced promotion of procoagulant reactions. These effects in concert with platelet activation may contribute to atherothrombotic complications in T2DM...
  44. ncbi Genetic heterogeneity of megalencephalic leukoencephalopathy and subcortical cysts
    C Patrono
    Unit of Molecular Medicine and Division of Pediatric Neurology, Bambino Gesu Children s Hospital, Rome, Italy
    Neurology 61:534-7. 2003
    ..Five patients did not harbor mutations in MLC1, supporting the existence of at least one other MLC locus...
  45. ncbi The future of antiplatelet therapy in cardiovascular disease
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Annu Rev Med 61:49-61. 2010
    ..Recent advances in the pharmacogenetics of thienopyridines open the realistic prospect of a personalized choice of the most appropriate antiplatelet agent and tailored dose adjustment for an individual patient...
  46. ncbi Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues
    Michael J Thun
    Department of Epidemiology and Surveillance Research, American Cancer Society, National Home Office, Atlanta, GA 30329 4251, USA
    J Natl Cancer Inst 94:252-66. 2002
    ..Finally, we suggest research opportunities that may help to accelerate the future clinical application of NSAIDs for cancer prevention or treatment...
  47. ncbi Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?
    Francesco Cipollone
    Arterioscler Thromb Vasc Biol 22:1516-8. 2002
  48. ncbi Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease
    Pietro Minuz
    Department of Biomedical and Surgical Sciences, University of Verona, Italy
    Circulation 106:2800-5. 2002
    ..Hypertensive patients with renovascular disease (RVD) may be exposed to increased oxidative stress, possibly related to activation of the renin-angiotensin system...
  49. ncbi Determinants of platelet activation in human essential hypertension
    Pietro Minuz
    Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy
    Hypertension 43:64-70. 2004
    ..These findings might help identify hypertensive patients who are at increased risk of cardiovascular events and who might benefit from long-term antiplatelet therapy...
  50. ncbi Determinants of platelet activation in Alzheimer's disease
    Giovanni Ciabattoni
    Center of Excellence on Aging, G d Annunzio University Foundation, Italy
    Neurobiol Aging 28:336-42. 2007
    ..To investigate the rate of platelet thromboxane (TX) biosynthesis and its determinants in Alzheimer's disease...
  51. ncbi Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
    Patricia M Kearney
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF
    BMJ 332:1302-8. 2006
    ..CONCLUSIONS: Selective COX 2 inhibitors are associated with a moderate increase in the risk of vascular events, as are high dose regimens of ibuprofen and diclofenac, but high dose naproxen is not associated with such an excess...
  52. ncbi Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease
    Giulia Renda
    Departments of Medicine and Clinical Sciences, Center of Excellence on Aging, G. D'Annunzio University, School of Medicine, Chiete, Italy
    Clin Pharmacol Ther 80:264-74. 2006
    ....
  53. ncbi Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
    Guido Finazzi
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    Blood 105:2664-70. 2005
    ..84-16.25; P = .0023), but not to hydroxyurea (HU) alone (HR, 0.86; 95% CI, 0.26-2.88; P = .8021), had an independent role in producing an excess risk for progression to AML/MDS compared with treatment with phlebotomy or interferon...
  54. ncbi Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal
    Colin Baigent
    Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK
    Arthritis Rheum 48:12-20. 2003
  55. ncbi Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets
    Bianca Rocca
    Research Center on Physiopathology of Hemostasis, Catholic University of Rome, 00168 Rome, Italy
    Proc Natl Acad Sci U S A 99:7634-9. 2002
    ....
  56. ncbi Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis
    Bianca Rocca
    Departments of Internal Medicine, Catholic University School of Medicine, 00168 Rome, Italy
    Exp Hematol 32:925-34. 2004
    ..The present study was aimed at characterizing the expression and activity of cyclooxygenase (COX) isoenzymes in erythropoiesis...
  57. ncbi Guest authorship, mortality reporting, and integrity in rofecoxib studies
    Carlo Patrono
    JAMA 300:901; author reply 904-5. 2008
  58. ncbi Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    Roberto Marchioli
    European Collaboration on Low Dose Aspirin in Polycythemia Vera Coordinating Centre, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
    J Clin Oncol 23:2224-32. 2005
    ..The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments...